Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibitor, Opdivo, has captured significant market share in the recurrent setting, relegating the combination of Eisai’s Lenvima/Kisplyx with Novartis’s Afinitor, Pfizer’s Inlyta, and single-agent mTOR inhibitors to later lines. In the first-line setting, the entry of Exelixis/Ipsen’s Cabometyx—and regimens that combine immune checkpoint inhibitors with angiogenesis inhibitors—look set to revolutionize the treatment of advanced disease. Following Sutent’s approval for high-risk early-stage (stage I-III) patients in the United States, multiple immune checkpoint inhibitors are anticipated to launch for early-stage treatment. Despite the increasing number of agents being approved for renal cell carcinoma, the substantial unmet need that remain means that developers of therapies that are more efficacious and/or safer than the current standards of care could reap high commercial rewards.
- How large are the early-stage and advanced or metastatic renal cell carcinoma drug-treatable populations? Will drug-treatment rates change over time?
- How is renal cell carcinoma currently treated, and what are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- Who are the key players developing combination therapies for renal cell carcinoma? How will these combination regimens be differentiated, and which look the most promising?
- Which emerging therapies we forecast will enter each of the renal cell carcinoma market segments? What uptake and sales are these therapies anticipated to secure?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: Twenty country-specific interviews with thought leaders (medical oncologists and urologists).
Key companies: Bristol-Myers Squibb/Ono Pharmaceutical, Merck & Co./MSD, Exelixis/Ipsen, and Pfizer.
Key drugs: Opdivo, Keytruda, Cabometyx, and Inlyta.
Population segments in market forecast: Early-stage (stage I-III) renal cell carcinoma, first-line advanced or metastatic renal cell carcinoma, second-line advanced or metastatic renal cell carcinoma, third-line advanced or metastatic renal cell carcinoma, and fourth-line advanced or metastatic renal cell carcinoma.
Emerging therapies: Phase III: 7 drugs; Phase II: 20 drugs; coverage of select Phase I and preclinical products.